Direct Oral Anticoagulants in Acute Coronary Syndrome

Seminars in Hematology

Volumn 51, Issue 2, 2014, Pages 147-151

  Ahrens, Ingo ^a   Bode, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CORONARY STENT; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART REINFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OCCLUSIVE CEREBROVASCULAR DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; FACTOR XA; HUMANS; ISCHEMIA; MORPHOLINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRAZOLES; PYRIDINES; PYRIDONES; THIOPHENES;

EID: 84901300427     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.03.004     Document Type: Article

References (16)

1. Merlini P.A., Bauer K.A., Oltrona L., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994, 90:61-68.
2. Steg P.G., James S.K., Atar D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012, 33:2569-2619.
3. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
4. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347:969-974.
5. van Es R.F., Jonker J.J., Verheugt F.W., et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002, 360:109-113.
6. Oldgren J., Budaj A., Granger C.B., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32:2781-2789.
7. Committee AS, Investigators, Alexander JH, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009, 119:2877-2885.
8. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011, 365:699-708.
9. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban v placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
10. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
11. Baim D.S., Carrozza J.P. Stent thrombosis. Closing in on the best preventive treatment. Circulation 1997, 95:1098-1100.
12. Palmerini T., Biondi-Zoccai G., et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012, 379:1393-1402.
13. Palmerini T., Kirtane A.J., Serruys P.W., et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv 2012, 5:357-364.
14. Gibson C.M., Chakrabarti A.K., Mega J., et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013, 62:286-290.
15. Mega J.L., Braunwald E., Murphy S.A., et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol 2013, 61:1853-1859.
16. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor v clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.